Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM.

Summary

This multi-society global guideline updates diagnosis and management recommendations for candidiasis, addressing emerging pathogens (e.g., Candida auris) and antifungal resistance amid recent taxonomic revisions. It highlights gaps in prior guidance and provides consolidated, evidence-informed recommendations across invasive and mucocutaneous disease.

Key Findings

• Highlights rising difficult-to-treat Candida infections driven by new host factors and antifungal resistance.
• Addresses emerging pathogens (Candida auris and fluconazole-resistant Candida parapsilosis) as global threats.
• Notes recent taxonomic revisions that may complicate clinical practice and provides updated recommendations.

Clinical Implications

Supports antifungal stewardship, diagnostic pathways, and treatment selection for both invasive and mucocutaneous candidiasis, including considerations for Candida auris and fluconazole-resistant C. parapsilosis, informing ICU protocols and perioperative prophylaxis/therapy.

Limitations

• Guideline/Review nature limits causal inference; recommendations depend on underlying evidence quality.
• Details on methodology and grading are not explicit in the abstract.

Future Directions

Implement guideline-concordant care pathways; evaluate outcomes and resistance trends; refine recommendations as new antifungals and diagnostics emerge.